We caught up with Principal Scientist Lindsay Denhoff (ICON; Dublin, Ireland) to discuss immunogenicity considerations for therapeutic proteins and the current analytical methodologies for detecting and characterizing anti-drug antibodies (ADAs). Lindsay shares some industry best practices for achieving high-quality ADA assays, as well as some of the advantages and limitations of singlicate ADA analysis compared with alternative techniques. We finish the interview with a look to the future where Lindsay discusses the emerging trends she's spotted in the field of immunogenicity and offers her predictions for how they may shape the future of therapeutic protein development.

ADA detection and characterization for immunogenicity testing: insights from ICON's Lindsay Denhoff

In this NCTalks podcast, Lauren Pulling, Editor of Neuro Central, is joined by Claude Wischik. Prof Wischik is board-certified in psychiatry and a professor of Old Age Psychiatry at the University of Aberdeen (UK). A pioneer in tau research, he discovered the tau protein compositional structure of Alzheimer’s tangles and established that it was possible to dissolve these tangles with pharmaceutically viable compounds that act as Tau Aggregation Inhibitors. Prof Wischik is also co-founder, chairman and chief executive of TauRx Therapeutics, which aims to develop new treatments for a range of neurodegenerative disorders, including Alzheimer’s disease.  In this interview, Prof Wischik discusses his 30 years’ experience in the field, the latest developments at TauRx, and what we can expect from tau research the next 10 years.

You can view more podcasts, plus the latest news and interviews with experts across neurology and neuroscience, at www.neuro-central.com.

ADA detection and characterization for immunogenicity testing: insights from ICON's Lindsay Denhoff

Taylor & Francis Group

Related tracks